Autolus Therapeutics Submits Fiscal Year 2018 Form 20-F

LONDON, Nov. 23, 2018 /PRNewswire/ -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has filed its annual report on Form 20-F for the fiscal year ended 2018 with the United States Securities and Exchange Commission. The annual report can be found on Autolus' investor relations website at

About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to:

              Investor contact:  
              International Media Contact:                    
              U.S. Media Contact:

     S.A. Noonan Communications    
     JW Communications                                          
     Rx Communications Group, LLC

     Susan A. Noonan               
     Julia Wilson                                               
     Paula Schwartz

           +44 (0)7818 430877 
     + 1-917-322-2216


View original content:

SOURCE Autolus Therapeutics plc